Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ciclosporin and refractory colitis.

A Barney Hawthorne¹

¹Department of Medicine, University Hospital of Wales, Heath Park, Cardiff, UK. Barney.Hawthorne@UHW-TR.wales.nhs.uk

European Journal of Gastroenterology & Hepatology

|March 1, 2003

Summary

Intravenous ciclosporin is a rapid, effective salvage therapy for refractory colitis, but carries risks of toxicity and long-term failure. Lower doses or alternative formulations may mitigate these adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Addressing real-world data gaps: estimating the uk population cost of crohn's disease and ulcerative colitis using a flexible cost-of-illness model informed by the optimal patient journey and IBDUK patient survey 2023.

BMC health services research·2026

Same author

The 2026 IBD UK Standards of healthcare service design and delivery for adults and children living with Crohn's disease and ulcerative colitis.

BMJ open gastroenterology·2026

Same author

Research engagement and patient-reported quality of care: a cross-sectional study of UK inflammatory bowel disease services.

BMJ open gastroenterology·2026

Same author

Comparative analysis of inflammatory bowel disease (IBD) patient- and service-reported quality of care using 2019 and 2023 UK benchmarking data from more than 26 000 adult patient respondents and 154 IBD services.

Journal of Crohn's & colitis·2026

Same author

Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study.

BMJ open gastroenterology·2024

Same author

Data linkage can reduce the burden and increase the opportunities in the implementation of Value-Based Health Care policy: a study in patients with ulcerative colitis (PROUD-UC Study).

International journal of population data science·2023

Area of Science:

Immunosuppressive therapy
Gastroenterology
Clinical pharmacology

Background:

Refractory colitis often necessitates colectomy.
Intravenous ciclosporin offers a salvage therapy option.
Ciclosporin use is associated with significant toxicity and long-term concerns.

Purpose of the Study:

To evaluate the efficacy and safety of intravenous ciclosporin as a salvage therapy for refractory colitis.
To identify strategies for mitigating ciclosporin toxicity.
To define the role of ciclosporin in the management of refractory colitis.

Main Methods:

Review of existing literature on intravenous ciclosporin for refractory colitis.
Analysis of reported efficacy, toxicity profiles, and failure rates.
Exploration of dose reduction and alternative formulations.

Main Results:

Intravenous ciclosporin demonstrates rapid efficacy in patients with refractory colitis.
Significant risks include opportunistic infections, renal, and neurotoxicity.
Optimal use involves short-term (3-6 months) bridging therapy to azathioprine or 6-mercaptopurine.

Conclusions:

Ciclosporin is a potent but hazardous therapy for refractory colitis.
Strategies like lower doses (2 mg/kg/day IV) or oral microemulsion may reduce toxicity.
Further research is needed to optimize ciclosporin's role and ensure patient safety.

Related Experiment Videos